These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 15880067)

  • 21. Early steroid withdrawal in solitary pancreas transplantation results in equivalent graft and patient survival compared with maintenance steroid therapy.
    Vessal G; Wiland AM; Philosophe B; Fink JC; Weir MR; Klassen DK
    Clin Transplant; 2007; 21(4):491-7. PubMed ID: 17645708
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation.
    Sarwal MM; Yorgin PD; Alexander S; Millan MT; Belson A; Belanger N; Granucci L; Major C; Costaglio C; Sanchez J; Orlandi P; Salvatierra O
    Transplantation; 2001 Jul; 72(1):13-21. PubMed ID: 11468528
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes of simultaneous kidney-pancreas transplantation with positive cross-match.
    Heilman RL; Chakkera H; Mazur M; Petrides S; Moss A; Mekeel K; Mulligan D; Reddy KS
    Transplant Proc; 2009; 41(1):303-6. PubMed ID: 19249540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation.
    Sampaio MS; Kadiyala A; Gill J; Bunnapradist S
    Transplantation; 2009 Oct; 88(7):904-10. PubMed ID: 19935462
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Depleting antibody induction in simultaneous pancreas-kidney transplantation: a prospective single-center comparison of alemtuzumab versus rabbit anti-thymocyte globulin.
    Stratta RJ; Rogers J; Orlando G; Farooq U; Al-Shraideh Y; Doares W; Kaczmorski S; Farney AC
    Expert Opin Biol Ther; 2014 Dec; 14(12):1723-30. PubMed ID: 25156622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
    Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
    Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Campath induction for kidney transplantation: report of 297 cases.
    Ortiz J; Palma-Vargas J; Wright F; Bingaman A; Agha I; Rosenblatt S; Foster P
    Transplantation; 2008 Jun; 85(11):1550-6. PubMed ID: 18551058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tacrolimus monotherapy following alemtuzumab induction in combined kidney-pancreas transplantation: results of a prospective randomized trial.
    Bösmüller C; Ollinger R; Sieb M; Weissenbacher A; Schneeberger S; Pratschke J; Margreiter R
    Ann Transplant; 2012 Dec; 17(4):45-51. PubMed ID: 23274323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Subcutaneous administration of alemtuzumab in simultaneous pancreas-kidney transplantation.
    Clatworthy MR; Sivaprakasam R; Butler AJ; Watson CJ
    Transplantation; 2007 Dec; 84(12):1563-7. PubMed ID: 18165765
    [TBL] [Abstract][Full Text] [Related]  

  • 30. No induction versus anti-IL2R induction therapy in simultaneous kidney pancreas transplantation: a comparative analysis.
    Becker LE; Nogueira VA; Abensur H; Miranda MP; Genzini T; Romão JE; Noronha IL
    Transplant Proc; 2006; 38(6):1933-6. PubMed ID: 16908327
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 5-year results of a prospective, randomized, single-center study of alemtuzumab compared with rabbit antithymocyte globulin induction in simultaneous kidney-pancreas transplantation.
    Stratta RJ; Rogers J; Orlando G; Farooq U; Al-Shraideh Y; Farney AC
    Transplant Proc; 2014; 46(6):1928-31. PubMed ID: 25131073
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Campath-1H in renal transplantation: The University of Wisconsin experience.
    Knechtle SJ; Fernandez LA; Pirsch JD; Becker BN; Chin LT; Becker YT; Odorico JS; D'alessandro AM; Sollinger HW
    Surgery; 2004 Oct; 136(4):754-60. PubMed ID: 15467659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alemtuzumab preconditioning allows steroid-calcineurin inhibitor-free regimen in live-donor kidney transplant.
    Refaie AF; Mahmoud KM; Ismail AM; Sheashaa HA; Kamal AI; Ghoneim MA
    Exp Clin Transplant; 2011 Oct; 9(5):295-301. PubMed ID: 21967254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thymoglobulin versus basiliximab induction therapy for simultaneous kidney-pancreas transplantation: impact on rejection, graft function, and long-term outcome.
    Bazerbachi F; Selzner M; Boehnert MU; Marquez MA; Norgate A; McGilvray ID; Schiff J; Cattral MS
    Transplantation; 2011 Nov; 92(9):1039-43. PubMed ID: 22002345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alemtuzumab induction in kidney transplantation: clinical results and impact on T-regulatory cells.
    Morales J; Bono MR; Fierro A; Iñiguez R; Zehnder C; Rosemblatt M; Calabran L; Herzog C; Benavente D; Aguiló J; Pefaur J; Alba A; Ferrario M; Simon W; Contreras L; Buckel E
    Transplant Proc; 2008 Nov; 40(9):3223-8. PubMed ID: 19010240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alemtuzumab induction in kidney transplantation.
    Huang E; Cho YW; Shah T; Peng A; Hayashi R; Bunnapradist S
    Clin Transpl; 2005; ():343-54. PubMed ID: 17424750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polyclonal versus monoclonal induction therapy in a calcineurin inhibitor-free immunosuppressive therapy in renal transplantation: a comparison of efficacy and costs.
    Sánchez-Escuredo A; Alsina A; Diekmann F; Revuelta I; Esforzado N; Ricart MJ; Cofan F; Fernandez E; Campistol JM; Oppenheimer F
    Transplant Proc; 2015; 47(1):45-9. PubMed ID: 25645767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improving results in solitary pancreas transplantation with portal-enteric drainage, thymoglobin induction, and tacrolimus/mycophenolate mofetil-based immunosuppression.
    Stratta RJ; Lo A; Shokouh-Amiri MH; Egidi MF; Gaber LW; Gaber AO
    Transpl Int; 2003 Mar; 16(3):154-60. PubMed ID: 12664209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation.
    Thomas PG; Woodside KJ; Lappin JA; Vaidya S; Rajaraman S; Gugliuzza KK
    Transplantation; 2007 Jun; 83(11):1509-12. PubMed ID: 17565326
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of outcomes after delayed graft function: sirolimus-based versus other calcineurin-inhibitor sparing induction immunosuppression regimens.
    McTaggart RA; Tomlanovich S; Bostrom A; Roberts JP; Feng S
    Transplantation; 2004 Aug; 78(3):475-80. PubMed ID: 15316379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.